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Introduction
Ubiquitous nuclear and cytoplasmic self-antigens that constitutively bind RNA are targeted selectively by the autoimmune response in several rheumatic diseases. Autoantibodies directed to one such antigen, La/Sj€ ogren's syndrome (SS)-B, occur at high prevalence in SS [1] and mothers of infants with congenital heart block or neonatal lupus syndrome [2] , and at lower prevalence in systemic lupus erythematosus (SLE) [3] . La-targeting antibodies cooccur typically with antibodies specific for Ro/SS-A [3] , associate with a higher frequency of extraglandular manifestations of SS including vasculitis, leukopenia, hypergammaglobulinaemia, restrictive pulmonary disease and internal organ involvement [4] [5] [6] and have been reported to associate selectively with vasculitis in SLE [7] . Deciphering mechanisms of normal immunological tolerance to RNA-binding nuclear antigens is essential for understanding the development of autoimmunity to such antigens and for designing effective therapies for mitigating the disorders in which they occur.
Anti-La autoantibody production is T helper celldependent, as suggested by the association with specific class II human leucocyte antigen (HLA) alleles [8] , classswitched isotypes [9] , somatic hypermutation [9] and high serum concentration [10] . Using mice expressing transgenic (Tg) human La (hLa) with ubiquitous, nuclear distribution at physiological levels, we have previously reported detectable immunological tolerance in hLaspecific CD4 1 T cells, but not in B lymphocytes [11, 12] . Further studies revealed that human La-specific T cells in double Tg mice for an I-E k -restricted T cell receptor (TCR) specific for hLa 67-76 peptide and the hLa neo-self-antigen undergo drastic but incomplete thymic clonal deletion [13] . A portion of residual, hLa-specific thymocytes in these mice developed into natural thymic regulatory T cells (T reg ), and the mice displayed high proportions of forkhead box P3 (FoxP3)-expressing, hLa-specific CD4 1 T cells in peripheral lymphoid organs that functioned to maintain immunological self-tolerance and prevent autoimmune lung pathology. However, it was possible that the lymphopenic environment caused by extensive thymic clonal deletion in this TCR/neo-self-antigen double Tg model was responsible for the increased proportion of T reg in the periphery of these mice.
CD4 1 FoxP3 1 T reg are important for controlling autoimmunity and can develop in response to self-antigen in the thymus [14] or in the periphery from mature, naive T cells that have completed T cell development [15, 16] . These cells suppress the responses of conventional T cells by several mechanisms, including immunosuppressive cytokines such as interleukin (IL)210 or transforming growth factor (TGF)-b and various cell contact-dependent mechanisms [17] . Both types of cells contribute to the circulating T reg pool, where they are regulated by homeostatic factors including IL-2 [18, 19] , TCR stimulation [20, 21] and costimulation [22] . TCR and co-stimulatory signals promoting maintenance or conversion of T reg in the periphery have been shown to be delivered by dendritic cells (DC) [23, 24] and, in some instances, B lymphocytes [25] [26] [27] , but the mechanisms involved are incompletely understood. DC subsets that have been implicated in peripheral T reg induction in settings of transplantation, low dose peptide-induced tolerance and the steady state include CD103 1 gut DC [28] , migratory dermal DC [29] and plasmacytoid pDC (pDC) [30] [31] [32] [33] . pDC may drive T reg development and expansion through low levels of antigen presentation and have been shown to promote T reg through production of indoleamine-2,3-dioxygenase (IDO), co-stimulatory molecules, secretion of granzyme B and production of retinoic acid [34, 35] . Existing studies have not addressed mechanisms of induction of T reg specific for ubiquitous, RNA-binding nuclear antigens often targeted in systemic rheumatic diseases.
In the present study, we assessed the fate of hLa-specific T cells introduced into the periphery of lymphocyte-replete mice expressing the hLa neo-self-antigen in order to understand peripheral T reg induction and homeostasis in T cells specific for a representative RNA-binding human nuclear autoantigen. We show that pDC induce expansion of hLaspecific FoxP3 1 T reg in a type I interferon (IFN)-dependent manner. These studies uncover a regulatory mechanism that should be considered in terms of prophylactic and therapeutic approaches for systemic rheumatic diseases that employ type I IFN blockade.
Materials and methods
Mice C57BL/6 (B6) mice congenic for H-2 k (B6.AK-H2 k /FlaEgJ; Jackson Laboratory, Bar Harbor, ME, USA) were crossed to B6 mice congenic for Thy1.1 (B6.PL-Thy1 a /CyJ; Jackson Laboratory) to generate B6.H-2 k/k .Thy1.1 1/1 mice. Line 3 hLa Tg mice described previously [11] were back-crossed to B6 mice at least 12 generations and crossed to B6.H-2 k/k .Thy1.1 1/1 congenic mice to generate heterozygous hLa transgenic (hLa Tg) or non-Tg H-2 k/k Thy1.1 1/1 and H-2 k/b Thy1.1 1/1 recipient mice. 3B5.8 1 hLa-specific TCR Tg mice described previously [13] were crossed to Tcra -/-(B6.129S2-Tcra tm1Mom /J; Jackson Laboratory) and B6.H-2 k congenic mice to generate B6.3B5.8 1/-.Tcra -/-.H-2 k/k and B6.3B5.8 1/-Tcra -/-.H-2 k/b donor mice that are naturally Thy1.2 1 . In addition, these donor mice were crossed with C57BL/6-FoxP3 tm1Flv /J mice (Jackson Laboratory), which express monomeric red fluorescent protein (mRFP)-tagged FoxP3, to generate B6.3B5.8 1/-.Tcra -/-.H-2 k/k .FoxP3-mRFP 1 donor mice that are naturally Thy1.2 1 .
Animals were maintained under specific pathogen-free barrier conditions in the OMRF Laboratory Animal Resource Center until experiments were carried out at 5-12 weeks of age. All studies were approved by the Oklahoma Medical Research Foundation Institutional Animal Care and Use committee.
Cell preparation
Splenocyte suspensions were obtained by passing spleens through 40 lm nylon filters, treating with Tris ammonium chloride solution (TAC; 0Á14 M NH 4 Cl in 17 mM Tris, pH 7Á2) to lyse red blood cells and washing in Dulbecco's modified Eagle's medium (Sigma-Aldrich, Inc., St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS), 13 non-essential amino acids (Life Technologies, Grand Island, NY, USA), 2 mM L-glutamine, 10 lg/ml penicillin/streptomycin, 50 lM b-mercaptoethanol and 2 mM sodium pyruvate. Cells from lymph nodes were obtained similarly but without TAC treatment. Cells were quantified using trypan blue exclusion.
Bulk CD4 1 T cells and sorted T reg were obtained from B6.3B5.8 1/-.Tcra -/-.H-2 k/k .FoxP3-mRFP donor mice by pre-purification using CD4 (L3T4) MicroBeads (Miltenyi Biotec, San Diego, CA, USA) positive selection according to the manufacturer's protocol, followed by sorting of mRFP -(FoxP3 -) cells on an Influx cell sorter (BD Biosciences, San Diego, CA, USA).
To obtain adequate numbers of conventional DC (cDC) and pDC, mice were implanted with 5 3 10 6 Fms-like pDC and type 1 interferon control T reg expansion V C 2016 British Society for Immunology, Clinical and Experimental Immunology, 186: 18-29 kinase 3 ligand (Flt3L)-secreting B16 melanoma cells by subcutaneous injection to induce DC expansion [36] . Within 2 weeks of implantation, spleens were harvested, diced and digested at 378C for 45 min in 10 ml RPMI-1640 supplemented with 10% FCS, 5 mM ethylenediamine tetraacetic acid (EDTA), 15 mM HEPES, 1 mg/ml collagenase D (Sigma-Aldrich) and 0Á1mg/mL DNase I (Roche Life Sciences, Indianapolis, IN, USA) followed by TAC treatment. CD11c 1 cells were enriched using CD11c MicroBeads (Miltenyi Biotec), according to the manufacturer's instructions. cDC and pDC were sorted further using antibodies directed to CD11c, CD19, CD317/PDCA1 and CD45R/ B220 on a high-speed MoFlo XDP1 cytometer (Beckman Coulter, Brea, CA, USA) at > 98% purity.
Donor T cells retrieved from recipient spleens for invitro experiments were selected positively using anti-Thy1.2 MicroBeads (Miltenyi Biotec) and further purified by MoFlo, sorting for Thy1.2 1 Thy1.1 -CD4 1 Vb10 1 donor cells. The T cell-depleted fraction was irradiated (2200 rads) and used as antigen-presenting cells (APC).
Adoptive transfer experiments
For T cell transfers, 4-6 3 10 7 unlabelled or 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFSE; Life Technologies, Grand Island, NY, USA)-labelled total splenocytes, 6 3 10 6 CFSE-labelled CD4 1 T cells or 2Á5 3 10 6 CD4 1 mRFP -(FoxP3 -) cells harvested from B6.3B5.8 1/-.Tcra -/-.H-2 k/k or B6.3B5.8 1/-.Tcra -/-.H-2 k/b donor mice were resuspended in 0Á2 ml phosphatebuffered saline (PBS) and injected retro-orbitally into hLa Tg or non-Tg H-2 k/k Thy1.1 1/1 or H-2 k/b Thy1.1 1/1 recipient mice, respectively. Seven days later (unless noted otherwise), spleens and lymph nodes from recipient mice were harvested and analysed by flow cytometry to assess cell proliferation, T reg accumulation and B cell and DC phenotype.
Recipient pDC depletion was carried out by treating recipient mice with intraperitoneal (i.p.) injections of 400 lg anti-pDC antibody (120G8.04; Imgenex; Novus Biologicals, Littleton, CO, USA) [37] or immunoglobulin (Ig)G isotype control (BioXCell, West Lebanon, NH, USA) every 48 h beginning 2 days prior to cell transfer. B cell depletion was carried out by i.p. injection of 250 lg anti-CD20 antibody (MB20-11; generously provided by Dr Thomas Tedder) or IgG isotype control antibody (BioXCell) every 48 h beginning 1 day prior to cell transfer. To block the type I IFN receptor, recipient mice were treated i.p. with anti-IFN-alpha/beta receptor alpha chain (IFNAR1) [38] [monoclonal antibody mouse IFNAR1 (MAR1)25A3; Leinco Technologies, St Louis, MO, USA] or IgG1 isotype control antibody (Bio-XCell). Antibody dosage began daily at 500 lg for the first 3 days (beginning 1 day prior to cell transfer) followed by 250 lg every 48 h thereafter until completion of the experiment.
Sorted splenic pDC were pulsed for 2 h with 10 lM hLa 61-84 peptide or hen egg-white lysozyme (HEL) 46-61 peptide in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 13 non-essential amino acids, 2 mM L-glutamine, 10 lg/ml penicillin/streptomycin, 50 lM b-mercaptoethanol and 2 mM sodium pyruvate at 1 3 10 6 cells/ml, washed twice and transferred subsequently (2 3 10 5 cells/recipient) into non-Tg H-2 k/k Thy1.1 1 recipient mice. The next day, 3B5.8 1 donor splenocytes were transferred into the same recipient mice. Euthanasia and cell retrieval were conducted 7 days post-3B5.8 T cell transfer.
Flow cytometry
Single-cell suspensions were treated with Fc block (anti-CD16/32 antibodies) for 5 min on ice, then stained with combinations of the following fluorophore-conjugated monoclonal antibody clones: CD4 (RM4-5), Vb10 (B21.5),
, B7-DC (TY25) and B7-H1 (MIH5). FoxP3 staining was performed using a commercial kit (FoxP3 Staining Kit; eBiosciences, San Diego, CA, USA), according to the manufacturer's instructions. Data were collected on an LSRII cytometer (BD Biosciences, San Diego, CA, USA) and analysed with FACSDiva (BD Biosciences) or FlowJo (Treestar, Ashland, OR, USA) software.
In-vitro assays
Antibodies directed to the hLa antigen were measured by enzyme-linked immunosorbent assay (ELISA) as described previously [11] from sera of recipient mice up to 20 days after adoptive transfer of 3B5.8 cells.
In-vitro proliferation assays were performed as described previously with slight modifications [39] . Briefly, B6.3B5.8 -.H-2 k/k .Tcra -/donor cells were transferred into hLa Tg and non-Tg mice as described above. Seven days post-transfer, donor CD4 1 T cells were isolated from recipients by positive selection with anti-Thy1.2 MicroBeads followed by cell sorting as described above. T cell depleted splenocytes were irradiated (2200 rads) and used as APC. Co-cultures containing a 1 : 4 T : APC ratio in the presence of 3Á7 lM hLa 61-84 peptide were conducted for 72 h; 1 lCurie/well of [ 3 H]-thymidine was added for the last 18 h. Cultures were harvested onto glass fibre filters and counted by liquid scintillation. Supernatant from cell cultures was obtained at 48 h in order to measure IL-10 (Invitrogen, now Life Technologies) and TGF-b (eBiosciences, San Diego, CA, USA) by ELISA according to the manufacturers' protocols.
To determine DC antigen presentation capacity, cDC and pDC were purified from Flt3L-induced Tg or non-Tg mouse spleens as detailed above. Varying numbers of DC were cultured with 1 3 10 5 3C5.5 hLa 61-84-specific T cell hybridoma cells [40] or 3A9 HEL 46-61-specific 3A9 hybridoma cells [41] in V-bottomed 96-well plates for 24 h. Culture supernatants were collected to measure IL-2 production by ELISA (OptEIA ELISA Set; BD Biosciences).
Statistical analysis
Pairwise comparisons were evaluated using Student's t-test. P-values less than 0Á05 were considered significant.
Results

The ubiquitous nuclear hLa neo-self-antigen induces expansion of antigen-specific T reg in the periphery of lymphocyte replete mice
To assess the post-thymic fate of T cells specific for a representative RNA-binding nuclear antigen, CFSE-labelled 3B5.8 TCR 1 hLa-specific T cells from Thy 1.2 1 B6.3B5.8 1/-H-2 k/b Tcra -/donor mice (referred to hereafter as 3B5.8 TCR Tg) were transferred adoptively into groups of H-2 k/b Thy1.1 1/1 recipient mice expressing the hLa neoself antigen (hereafter referred to as hLa Tg). Recipients were Tg for the complete human gene for La, including its natural promotor, and expressed nuclear-localized hLa ubiquitously at levels similar to the endogenous mouse La protein [11] . Donor cells were recovered from secondary lymphoid organs of recipient mice 7 days post-transfer and examined for proliferation status. As assessed by the fraction of cells diluting CFSE, donor CD4 1 T cells divided extensively in hLa Tg (median 84Á9% CFSE low fraction, range 82Á1-86.7%, n 5 4) but not non-Tg (median 7Á1%, range 7Á1-12Á6%, n 5 3) recipients by the 7-day time point ( Fig. 1a) . Similar results were observed in H-2 k/k recipients (Supporting information, Fig. S1 ).
The hLa Tg recipient mice produced low, but detectable, levels of anti-La antibodies 14 and 20 days post-transfer (Supporting information, Fig. S2 ); total body pathological examination 20 days post-transfer revealed no evidence of lymphoid cell infiltrates in any tissues or organs, and all blood cell counts were normal (data not shown). As these observations suggested potential control of autoreactivity by tolerogenic mechanisms, the potential development of peripheral T reg in the model was evaluated. Donor splenocytes were transferred retro-orbitally into groups of hLa Tg and non-Tg recipient mice as discussed above. Seven days post-transfer, splenocytes and lymph node cells were recovered from recipients and analysed by flow cytometry for the expression of CD25 and the transcription factor, FoxP3. Increased frequencies and absolute numbers of donor cells with CD25 1 FoxP3 1 and CD25 -FoxP3 1 T reg phenotypes were recovered from hLa Tg recipient spleens (Fig. 1b ,c) and lymph nodes (not shown) compared to those of non-Tg recipient mice. Similar results were observed in H-2 k/k and H-2 k/b recipient mice; thus, H-2 k/k and H-2 k/b transfer models were used interchangeably in subsequent experiments. In summary, 3B5.8 donor T cells recognize and respond to the hLa antigen as identified by cellular proliferation and accumulation of cells with a T reg phenotype.
To determine if the accumulation of T reg in this model arises from de-novo differentiation or marked expansion of small numbers of pre-existing T reg , donor mice expressing a red fluorescent protein (RFP)-tagged FoxP3 locus [42] were employed. In this case total purified CD4 1 T cells, which included a small percentage of contaminating RFP 1 T reg cells, or RFP -CD4 1 (FoxP3 -) non-T reg cells purified (at $99% purity) from FoxP3-RFP donor mice ( Fig. 2a) were transferred into recipient mice as described above. Spleen cells recovered from recipients 7 days post-transfer were analysed by flow cytometry for the frequency of donor RFP 1 (FoxP3 1 ) T cells. Both the bulk CD4 1 and highly purified RFP -CD4 1 donor T cell populations were capable of generating RFP 1 T reg following transfer into hLa Tg recipient mice, while RFP 1 cells were absent following transfer into non-Tg recipients (Fig. 2b ). Furthermore, more extensive amplification of T reg cells occurred in hLa Tg recipients that received bulk CD4 1 T cells compared to those that received sorted CD4 1 RFPnon-T reg cells (Fig.  2b) . Therefore, the increased T reg in hLa Tg recipients is due primarily to the expansion of pre-existing T reg , although de-novo differentiation occurs to a lesser extent.
To examine further the characteristics of hLa-specific donor T cells after retrieval from hLa Tg mice, proliferation and production of immunosuppressive cytokines in response to in-vitro antigenic challenge were assessed. Donor cells retrieved from recipient mice 7 days posttransfer and challenged with hLa 61-84 peptide in vitro exhibited defective proliferation and secreted IL-10 ( Fig. 3 ). TGF-b1 was undetectable under similar conditions (data not shown). Plasmacytoid dendritic cells but not B lymphocytes promote expansion of hLa-specific T reg B lymphocytes and pDC have been implicated selectively in pathogenic responses to RNA-binding nuclear antigens such as La [43] and have also been shown to aid in the generation of peripheral T reg . To determine if these cell types drive peripheral expansion of T reg in the present model, recipient mice were depleted selectively of these cells throughout the duration of the experiment. Treatment of hLa Tg recipient mice with B cell-or pDC-depleting antibodies resulted in elimination of B lymphocytes (Supporting information, Fig. S3 ) or pDC (Supporting information, Fig. S4 ), respectively. B lymphocytes were not required for the increased appearance of donor-derived T reg (Fig. 4a,b) . In contrast, depletion of pDC impaired the development of hLa-specific T reg in hLa Tg recipient mice significantly (Fig.  4c,d) . Thus, pDC but not B lymphocytes promote peripheral expansion of T reg specific for a ubiquitous, RNAbinding nuclear antigen.
To determine whether previously proposed tolerogenic (CD199/CCR9 [32] , CD200 [44] and CD9 [45] ), coinhibitory (CD274/B7-H1/PDL-1 and CD273/B7-DC/PD-L2) or co-stimulatory (CD80 and CD86) markers were expressed selectively on pDC following adoptive transfer of hLa-specific donor cells, recipient pDC (CD11c 1 CD45R/ B220 1 CD317/120G8 1 CD317/PDCA1 1 ) and B lymphocytes (CD45R/B220 1 CD11c -), were characterized phenotypically 7 days post-transfer. Compared to B cells, pDC exhibited increased expression of MHC class II, CD199/CCR9, CD200, CD9, CD80 and CD86, as well CD274/B7-H1 and CD273/ B7-DC ( Fig. 5 ). Compared to cDC (CD11c 1 CD45R/ B220 -CD317/120G8 -CD317/PDCA1 -), pDC expressed lower levels of MHC class II and CD9 and increased expression of CD199/CCR9, CD200, CD274/B7-H1and CD273/B7-DC (Supporting information, Fig. S5 ).
hLa Tg pDC constitutively present the hLa 61-84 epitope and autonomously induce 3B5. 8 
T reg in vivo
We have shown previously that hLa Tg B lymphocytes constitutively present hLa T cell epitopes [11] . To determine whether pDC and cDC constitutively present the hLa 61-84 epitope in vivo in hLa Tg recipient mice, pDC and cDC from both hLa Tg and non-Tg mice were sorted and cocultured with an I-E k -restricted hLa 61-84-specific T cell hybridoma in the absence of any exogenous hLa antigen. Following 24-h co-culture, IL-2 production was measured from cell culture supernatants. Compared to those from microcultures containing non-Tg DC, hLa-specific T cells from microcultures containing hLa Tg cDC and, to a lesser extent, hLa Tg pDC, secreted increasing IL-2 with increasing DC numbers (Fig. 6a) , indicating constitutive presentation of the hLa 61-84 epitope by cDC and pDC in hLa Tg mice. In contrast, cDC and pDC isolated from hLa Tg mice failed to elicit responses from the 3A9 T cell hybridoma that is specific for an I-A k -restricted epitope of the irrelevant HEL antigen.
To determine whether hLa peptide-loaded pDC alone from non-Tg mice could induce 3B5.8 T reg expansion in the absence of endogenously expressed hLa antigen in vivo, highly purified pDC were loaded with either hLa 61-84 peptide or irrelevant control I-A k -restricted HEL 46-61 peptide and transferred subsequently into non-Tg recipient mice. Peptide loading was confirmed by the capacity of peptide-loaded DC to specifically stimulate the relevant hybridomas (Supporting information, Fig. S6 ). The following day, cells from 3B5.8 1 donor mice were also transferred into recipient mice. Seven days after donor T cell transfer, spleens were harvested and donor 3B5.8 T reg were assessed by flow cytometry as in earlier experiments. pDC loaded with hLa peptide, but not pDC loaded with control peptide, induced accumulation of 3B5.8 TCR-expressing T reg (Fig. 6c,d) . Thus, pDC not only present the hLa antigen constitutively in hLa Tg mice, but can also promote the generation of antigen-specific T reg when provided as the sole hLa 61-84 peptide-presenting cell in vivo.
Type 1 IFN enhances hLa-specific T reg expansion
pDC are specialized type I IFN-producing cells [43] . In the present model, pDC are also important mediators in promoting self-antigen-specific T reg . To determine whether type I IFN contributes to the enhanced generation of hLaspecific T reg in the periphery of hLa Tg mice, hLa Tg recipients were treated with a blocking monoclonal antibody specific for the IFN-a/b (IFN-a/b) receptor, IFNAR1, throughout the T cell adoptive transfer experiment. Numbers of hLa-specific T reg were reduced significantly among anti-IFNAR1 antibody-treated hLa Tg recipient mice compared to those that had been treated with an isotype control antibody (Fig. 7) . Therefore, type I IFN promotes accumulation of donor hLa-specific FoxP3 1 regulatory T cells in the periphery of hLa Tg recipient mice.
Discussion
RNA-binding antigens are key targets of the autoimmune response in several rheumatic diseases, a phenomenon that is thought to arise from the capacity of RNA-binding nuclear antigen-containing immune complexes to stimulate RNA sensors in accessory cells such as B lymphocytes and pDC [43] . Mechanisms of normal immunological tolerance to this class of self-antigen have not been well studied. Moreover, although T reg are recognized as critical for the control of autoimmune disease, mechanistic details of their regulation are still incomplete. We observed recently that thymic clonal deletion and development of thymic T reg are important mechanisms of tolerance to the hLa neo-selfantigen that act to prevent high titres of anti-hLa autoantibodies, cellular autoimmunity and pulmonary pathology [13] . Herein we investigated the regulation of hLa antigenspecific T reg in the periphery of mice using an adoptive transfer system.
The data presented show that a representative, ubiquitously expressed RNA-binding nuclear antigen can elicit antigen-specific T reg in the periphery of mice. Antigen exposure without concurrent inflammation may promote conversion of FoxP3 -T cells into FoxP3 1 T reg [46] . Although there was evidence for de-novo T reg differentiation in the hLa-specific donor T cell/hLa Tg recipient adoptive transfer model, the major effect was expansion of preexisting T reg . In the present study, donor T cells proliferated in recipient mice and induced low, but detectable, levels of autoantibodies directed to the hLa neo-self-antigen. Using adoptive transfer of hLa 61-84 peptide-primed polyclonal T cells, we established previously that non-tolerant donor cells can, at least transiently, elicit autoantibodies in hLa Tg recipient mice, while CD4 1 T cells from tolerant hLa Tg donor mice cannot [11] . The La autoantibodies observed in the present study were of lower titre at all time-points compared to the prior study, despite transfer of much higher numbers of hLa-specific donor T cells. We speculate that the low autoantibody levels and lack of autoimmune pathology following the transfer of large numbers of hLaspecific T cells from TCR Tg donor mice were limited by the observed expansion of T reg . This thesis is supported by our recent study showing that impairment of thymic T reg differentiation and T reg function in a hLa/TCR double Tg mouse model led to high titre hLa autoantibody responses and subsequent autoimmune lung pathology [13] . Understanding the mechanisms of RNA-binding nuclear antigenspecific T reg accrual may permit the design of rheumatic disease-targeted therapies that can preserve this beneficial regulatory response selectively while simultaneously curtailing pathogenic cell subsets.
The pDC and B lymphocyte subsets are major pathogenic cell types in lupus and related disorders such as SS and are the targets of existing or developing therapies [47, 48] . The present studies show clearly that pDC but not B cells are required for efficient peripheral T reg expansion, as their elimination in recipient mice hampered hLaspecific T reg accumulation severely in the adoptive transfer model. The mechanism of pDC expansion involved antigen presentation, as hLa peptide-loaded pDC alone could elicit hLa-specific T reg expansion in vivo in the absence of any other hLa antigen source. Moreover, pDC from hLa Tg recipient mice presented endogenous hLa peptide constitutively, but at a lower level than conventional DC as measured by the readout of hLa 61-84 peptide-specific hybridoma stimulation and by cell surface MHC class II levels. This is consistent with high rates of MHC class II turnover among activated pDC that keeps presentation of specific antigens low [49] and with induction of T reg by low peptide concentrations [31] .
Cell surface phenotyping of recipient T reg -inducing pDC revealed expression of tolerogenic pDC markers reported by others, as well as enhanced expression of both costimulatory and co-inhibitory markers, all of which could contribute mechanistically to T reg expansion. In particular, pDC in our model expressed high levels of CD199/CCR9, reported to be a marker for tolerogenic, immature DC that control graft-versus-host disease by enhancing T reg function [32] . Tolerogenic pDC in our model also expressed CD200, which can induce T reg through an IDO-dependent mechanism [44] . Interestingly, only activated pDC can secrete IDO [44] . Low levels of CD9 were reported previously to mark tolerogenic immature pDC that produced negligible levels of IFN-a, while CD9 1 pDC were immunostimulatory and secreted IFN-a in response to Toll-like receptor ligation [45] . In the present study, the tolerogenic pDC expressed CD9 levels that were intermediate between B cells and cDC, consistent with a phenotype permissive for IFN-a secretion. Although the role of immature DC in inducing T reg is established, mature DC expressing high levels of co-stimulatory molecules can also expand T reg preferentially [50, 51] . Moreover, B7-H1 has been implicated in T reg expansion in the settings of infection [52, 53] and allergy [54] . A similar role for CD273/B7-DC can be hypothesized, as these two ligands share the same receptor. Taken together, the phenotype of tolerogenic pDC in hLa Tg recipient mice is consistent with recently activated immature pDC. Further studies will be required to explore systematically the relevance of individual surface markers to the expansion of T reg specific for ubiquitous RNA-binding nuclear antigens.
Although elevated type 1 IFN levels are pathogenic in SLE and related disorders, we observed that the mechanism of expansion of T reg specific for the representative RNA-binding nuclear antigen La was promoted by type 1 IFN. Thus, blockade of the type 1 IFN receptor IFNAR1 hampered T reg accumulation of hLa-specific T cells severely after transfer into hLa Tg mice in this tolerogenic model. The present studies have not established the cellular source of T reg -promoting type 1 IFN in the hLa adoptive transfer model; however, it is reasonable to speculate that the source may be pDC. CD200 can modulate type 1 IFN secretion by myeloid cells [55] . Thus, elevated CD200 expression and intermediate levels of CD9 [45] may mark pDC with the capacity to produce tolerogenic, non-pathogenic levels of type 1 IFN that promote T reg accumulation. While the present paper was in preparation, Metidji and colleagues used IFNAR1-deficient mice to show that type 1 IFN promotes development of thymic T reg and survival of T reg in the periphery of mice in a competitive or stress environment [56] .
We conclude that pDC and type 1 IFN are important mechanisms controlling accumulation of RNA-binding nuclear antigen-specific T reg in the periphery. These results inform prophylactic and therapeutic approaches for preventing and treating rheumatic autoimmune diseases wherein B cell depleting therapies may spare T reg , while IFN-a blockade may inhibit not only pathogenic responses but also beneficial T reg expansion.
Supporting information
Additional Supporting information may be found in the online version of this article at the publisher's web-site: . Cells were pre-gated on MHC class II 1 cells for the evaluation of MHC class II MFI values. Black line indicates isotype control from CD11c 1 B220cells. Statistics were calculated using Student's t-test. *P < 0Á05; **P < 0Á01; ***P <0Á001; ****P < 0Á0001. Fig. S6 . Verification of peptide loading onto major histocompatibility complex (MHC) class II of plasmacytoid dendritic cells (pDC). Sorted pDC from Fms-like kinase 3 ligand (Flt3L)-induced wild-type B6 mice congenic for H-2 k (isolated from splenocytes pooled from two to three mice/group) were loaded with 10 lM of hLa 61-84 peptide (a) or hen egg-white lysozyme (HEL) 46-61 peptide (b) in vitro for 2 h, washed twice, then tested (8 3 10 3 peptide-loaded DC per well) for the capacity to stimulate the 3C5.5 hLa 61-84-specific T cell hybridoma or the 3A9 HEL 46-61-specific T cell hybridoma (1 3 10 5 hybridoma cells/well). In comparison, direct stimulation of 3C5.5 (c) and 3A9 (d) with peptides in the presence of irradiated splenic antigen-presenting cells (APC) (3 3 105 cells/well) demonstrates the greater inherent responsiveness of the 3C5.5 hybridoma compared to the 3A9 hybridoma for specific antigenic peptide. All results are the mean 6 standard deviation (s.d.) of triplicate wells.
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